Isocitrate Dehydrogenase Inhibitors in Acute Myeloid Leukemia.
Mutations in isocitrate dehydrogenase genes (IDH1 and IDH2) are common in acute myeloid leukemia (AML), occurring in up to 30% of AML cases.
APA
Dai Q, Yang Z, et al. (2026). Isocitrate Dehydrogenase Inhibitors in Acute Myeloid Leukemia.. Chemistry & biodiversity, 23(2), e03194. https://doi.org/10.1002/cbdv.202503194
MLA
Dai Q, et al.. "Isocitrate Dehydrogenase Inhibitors in Acute Myeloid Leukemia.." Chemistry & biodiversity, vol. 23, no. 2, 2026, pp. e03194.
PMID
41662580
Abstract
Mutations in isocitrate dehydrogenase genes (IDH1 and IDH2) are common in acute myeloid leukemia (AML), occurring in up to 30% of AML cases. Mutations in IDH lead to abnormal epigenetic regulation in AML cells and block differentiation. Inhibitors of mutated IDH1 and IDH2, vorasidenib, ivosidenib, olutasidenib, and enasidenib, respectively, were recently approved by the FDA for relapsed/refractory AML. In this review, we mainly focus on IDH inhibitors in leukemia therapy, including the discovery, structure optimization, activity of IDH inhibitors, and applications, which provided the reference for the discovery of new anticancer agents.
MeSH Terms
Isocitrate Dehydrogenase; Humans; Leukemia, Myeloid, Acute; Enzyme Inhibitors; Antineoplastic Agents; Mutation
같은 제1저자의 인용 많은 논문 (5)
- TIAL1 regulates the Hippo pathway through an RNA-binding-independent mechanism.
- Manipulation of Wnt/β-Catenin Signaling by Synthetic Frizzled Agonist and LRP Antagonist in Organoid Cultures and In Vivo.
- Tumor associated neutrophils promote prostate cancer progression by mediating neutrophil trap secretion through PSMA1- NF-κB-HIF-1α signaling axis.
- From immune suppression to immunotherapy sensitization: the dual roles of circRNAs in cancer progression.
- Clinicopathological features and prognostic factors analysis of multiple synchronous distinct subtypes of primary thyroid carcinoma.